• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    11/21/23 8:06:41 AM ET
    $ALZN
    $BCLI
    $CDIO
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALZN alert in real time by email

    Gainers

    • SILO Pharma (NASDAQ:SILO) shares increased by 36.2% to $2.22 during Tuesday's pre-market session. The company's market cap stands at $6.9 million.
    • TRACON Pharma (NASDAQ:TCON) shares increased by 30.02% to $0.23. The market value of their outstanding shares is at $7.0 million.
    • Fresh2 Group (NASDAQ:FRES) shares increased by 28.4% to $1.22. The market value of their outstanding shares is at $17.9 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares increased by 22.03% to $0.22. The company's market cap stands at $10.7 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 19.23% to $0.62. The company's market cap stands at $5.8 million.
    • Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 17.47% to $2.42. The market value of their outstanding shares is at $133.2 million.

    Losers

    • MorphoSys (NASDAQ:MOR) shares fell 24.1% to $4.45 during Tuesday's pre-market session. The market value of their outstanding shares is at $608.2 million. As per the press release, Q3 earnings came out 4 days ago.
    • Alzamend Neuro (NASDAQ:ALZN) shares declined by 13.67% to $1.2. The market value of their outstanding shares is at $7.7 million.
    • Enzo Biochem (NYSE:ENZ) stock fell 13.39% to $1.1. The market value of their outstanding shares is at $55.5 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares decreased by 12.22% to $1.94. The company's market cap stands at $36.3 million.
    • Sharps Technology (NASDAQ:STSS) shares decreased by 11.91% to $0.41. The company's market cap stands at $6.2 million.
    • Nemaura Medical (NASDAQ:NMRD) stock fell 10.17% to $0.21. The market value of their outstanding shares is at $6.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALZN
    $BCLI
    $CDIO
    $CNTB

    CompanyDatePrice TargetRatingAnalyst
    Connect Biopharma Holdings Limited
    $CNTB
    12/1/2025$9.00Buy
    Lake Street
    Connect Biopharma Holdings Limited
    $CNTB
    10/31/2025$10.00Buy
    BTIG Research
    Connect Biopharma Holdings Limited
    $CNTB
    6/12/2025$7.00Buy
    H.C. Wainwright
    MorphoSys AG
    $MOR
    3/14/2024Overweight → Equal Weight
    Wells Fargo
    Connect Biopharma Holdings Limited
    $CNTB
    3/4/2024$7.00Buy
    H.C. Wainwright
    MorphoSys AG
    $MOR
    1/16/2024$9.19 → $10.40Overweight → Equal-Weight
    Morgan Stanley
    MorphoSys AG
    $MOR
    10/13/2023$3.70 → $9.19Underweight → Overweight
    Morgan Stanley
    MorphoSys AG
    $MOR
    9/15/2023$3.50 → $9.25Sell → Neutral
    Goldman
    More analyst ratings

    $ALZN
    $BCLI
    $CDIO
    $CNTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Falconx Holdings Ltd sold $1,490,755 worth of shares (769,320 units at $1.94) and exercised 461,538 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:45:04 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    New insider Falconx Holdings Ltd claimed ownership of 769,230 shares (SEC Form 3)

    3 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:10:05 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Large owner Saba Capital Management, L.P. sold $86,371 worth of shares (37,182 units at $2.32) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    1/20/26 5:55:14 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $ALZN
    $BCLI
    $CDIO
    $CNTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Connect Biopharma with a new price target

    Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00

    12/1/25 9:37:24 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Connect Biopharma with a new price target

    BTIG Research initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $10.00

    10/31/25 8:19:20 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Connect Biopharma with a new price target

    H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00

    6/12/25 7:54:22 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $BCLI
    $CDIO
    $CNTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026 at 8:00 a.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference. About

    3/3/26 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

    NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a second definitive agreement for an additional $1 million strategic private placement. This brings the total capital raised in February 2026 to $2 million. The financing is expected to reinforce a stable valuation for the company and provides the near-term resources required to advance its immediate regulatory and clinical objectives.Key Terms of the Second Placement:Market-Aligned Pricing: The common stock was priced at $0.60 per share, closely aligned with recent market performance (clo

    2/26/26 6:22:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sharps Technology and The Tie Announce Strategic Collaboration to Advance Institutional Participation in the Solana Ecosystem

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ:STSS), a medical device company with a Solana digital asset treasury strategy, and The Tie, Inc. ("The Tie"), the leading provider of institutional-grade digital asset analytics, compliant communications, and infrastructure services, today announced a strategic collaboration to strengthen Solana's institutional infrastructure and expand institutional access to the ecosystem. Under the collaboration, STSS will delegate a portion of its SOL treasury holdings, currently more than 2 million SOL, to Stakin by The Tie, which operates non-custodial validator infrastructure across 40+ proof-o

    2/25/26 9:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $ALZN
    $BCLI
    $CDIO
    $CNTB
    SEC Filings

    View All

    SEC Form 424B5 filed by Alzamend Neuro Inc.

    424B5 - Alzamend Neuro, Inc. (0001677077) (Filer)

    3/6/26 4:46:18 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Alzamend Neuro, Inc. (0001677077) (Filer)

    3/6/26 4:30:37 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    2/27/26 4:24:56 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALZN
    $BCLI
    $CDIO
    $CNTB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $ALZN
    $BCLI
    $CDIO
    $CNTB
    Leadership Updates

    Live Leadership Updates

    View All

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

    – Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. "We are pleased to welcome Jim to our Board of Directors," sai

    7/22/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Attovia Therapeutics Appoints Chief Financial Officer

    FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ:CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory diseases. At Attovia, Mr. Chan will lead the company's finance and operations functions and serve on its Executive Committee, reporting to Tao Fu, Chief Executive Officer. "I am delighted to welcome Steve to Attovia at this critical growth period for the company. He brings over thirt

    10/15/24 7:30:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $BCLI
    $CDIO
    $CNTB
    Financials

    Live finance-specific insights

    View All

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We have been working closely with our network of clinical sites and with our selected manufacturing partners to ensure operational readiness. We also continue to engage with

    11/14/25 4:30:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

    Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

    10/6/25 8:10:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $ALZN
    $BCLI
    $CDIO
    $CNTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

    SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

    11/14/24 3:24:53 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care